Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments Short Sales Trader Talk Trading Halts

Rodman & Renshaw Reiterates Buy Rating on Valeant (VRX) July 20, 2016 8:02 AM Valeant (VRX) Pipeline Developments 'Positive', But In-Line with Expectations - BMO CapitalJuly 20, 2016 7:40 AM FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque PsoriasisJuly 19, 2016 4:27 PM Valeant Pharma's (VRX) psoriasis drug should be approved with risk management - BloombergJuly 19, 2016 3:20 PM Valeant Pharma (VRX) AdCom on Brodalumab BeginsJuly 19, 2016 8:10 AM Valeant (VRX) Scripts Plunge Amid 4-Day WeekJuly 18, 2016 10:16 AM